A new model, TxGNN, revolutionizes zero-shot drug repurposing by predicting treatments for diseases with no known therapies, offering improved accuracy and trust via interpretable AI explanations.
Pfizer Australia and BioNTech announce TGA approval for Omicron XBB.1.5-adapted monovalent COVID-19 vaccine
Pfizer Australia and BioNTech SE today announced that the Therapeutic Goods Administration (TGA) have authorised the companies’ XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) in